Get the Stockscreener App
2.64
10.51%
-0.31
Biora Therapeutics Inc stock is traded at $2.64, with a volume of 108.24K.
It is down -10.51% in the last 24 hours and down -53.98% over the past month.
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology.
See More
Previous Close:
$2.95
Open:
$2.82
24h Volume:
108.24K
Relative Volume:
2.66
Market Cap:
$10.79M
Revenue:
$98,000
Net Income/Loss:
$-86.59M
P/E Ratio:
-0.4844
EPS:
-5.45
Net Cash Flow:
$-48.49M
1W Performance:
-25.21%
1M Performance:
-53.98%
6M Performance:
-63.89%
1Y Performance:
-86.03%
1-Day Range:
$2.38
$2.84
1-Week Range:
$2.38
$3.5999
52-Week Range:
$2.38
$19.90
Biora Therapeutics Inc Stock (BIOR) Company Profile
Name
Biora Therapeutics Inc
Sector
Industry
Phone
855-293-2639
Address
4330 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Biora Therapeutics Inc Stock (BIOR) Latest News
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
SEC Form 424B5 filed by Biora Therapeutics Inc. - Quantisnow
SEC Form 424B3 filed by Biora Therapeutics Inc. - Quantisnow
Biora Therapeutics announces $3 million stock and warrant sale - Investing.com India
Biora Therapeutics advances oral drug delivery tech By Investing.com - Investing.com Nigeria
Biora Therapeutics advances oral drug delivery tech - Investing.com India
Biora Therapeutics Shares Progress on Smaller BioJet™ - GlobeNewswire
Biora Therapeutics Shares Progress on Smaller BioJet™ Clinical Device with Largest Payload of any Ingestible Injectable at the 14th Annual PODD Meeting - StockTitan
Biora Therapeutics Inc’s results are impressive - US Post News
Market Highlights: Biora Therapeutics Inc (BIOR) Ends on a Low Note at 0.55 - The Dwinnex
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting - The Manila Times
Biora Therapeutics to Reveal 00-Size BioJet™ Device at the - GlobeNewswire
Biora Therapeutics enacts reverse stock split, adjusts shares By Investing.com - Investing.com Australia
Biora Therapeutics enacts reverse stock split, adjusts shares - Investing.com India
Biora Therapeutics to Present at the 19th Annual Peptide Therapeutics Symposium - The Manila Times
Biora Therapeutics Announces Award-Winning Abstract to be - GlobeNewswire
Biora Therapeutics Announces Award-Winning Abstract to be Presented at American College of Gastroenterology Annual Scientific Meeting 2024 - Yahoo Finance
Biora Therapeutics Inc’s Market Journey: Closing Weak at 0.59, Down -9.63 - The Dwinnex
Biora Therapeutics Inc Inc. (BIOR) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Biora Therapeutics secures additional $4 million financing - Investing.com India
Biora Therapeutics secures additional $4 million financing By Investing.com - Investing.com UK
Biora Therapeutics Achieves ISO 13485 Certification - GlobeNewswire
A History of Outperforming Analyst Forecasts and Beating the Odds: Biora Therapeutics Inc (BIOR) - SETE News
Biora Therapeutics Announces Positive Nasdaq Listing Decision - GlobeNewswire
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Biora Therapeutics secures new financial agreements - Investing.com India
BIOR: Second Quarter Results - Yahoo Finance
Biora Therapeutics, Inc. (NASDAQ:BIOR) Forecasted to Post Q3 2024 Earnings of ($0.42) Per Share - Defense World
BIOR’s Stock Woes: Down -20.37% in 6 Months, Down -20.37% in Just 5 Days - The InvestChronicle
Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023) - Yahoo Finance
Biora Therapeutics (NASDAQ:BIOR) Receives “Buy” Rating from HC Wainwright - Defense World
Biora Therapeutics, Inc. (NASDAQ:BIOR) Q2 2024 Earnings Call Transcript - Insider Monkey
Biora Therapeutics maintains stock target after strong Q2 results By Investing.com - Investing.com UK
Earnings call: Biora Therapeutics reports progress on BT-600 and BioJet platforms - Investing.com
Biora Therapeutics Inc (BIOR) Q2 2024 Earnings Call Transcript H - GuruFocus.com
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024 - MSN
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript - Seeking Alpha
Biora Therapeutics Announces Funding Agreement with Existing Investors - GlobeNewswire
Biora Therapeutics Restructures Debt and Issues New Securities - TipRanks
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results - GlobeNewswire
Biora Therapeutics Inc Stock (BIOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):